Sahajanand Medical Technologies to Invest 250 cr in Telangana

IMT News Desk
IMT News Desk
· 2 min read
SMT
K T Rama Rao Minister for Industries Telangana and Bhargav Kotadia, MD, SMT with other dignitaries
SMT (Sahajanand Medical Technologies) a leading medical devices company, based at Surat, today announced that it will invest 250 Cr in a manufacturing unit in Telangana. Bhargav Kotadia, MD, SMT met K T Rama Rao, Minister for Industry & Commerce, Municipal Administration & Urban Development, ITE&C, Mines, Handlooms & Textiles, NRI Affairs at Camp Office today. Ganesh Sabat, CEO, SMT; Ashish Agrawal, CFO, SMT;  Jayesh Ranjan, Principal Secretary of the Industries & Commerce (I&C) and Information Technology (IT) Departments and Shakthi Nagappan, Director for Life Sciences and Pharmaceutical were also part of the meeting.
Later in the day K T Rama Rao tweeted about the meeting.
https://bit.ly/2Nhvq1p
According to the tweet, SMT has announced an investment of Rs 250 crore to set up an integrated manufacturing unit of minimally invasive life-saving medical devices at the Medical Device Park, Sultanpur.
SMT will manufacture 1.2 Mn stents and 2 MN balloon catheters in this facility, with an investment of over Rs. 250 crores and will create more than 2000 direct jobs at the Medical devices park in Sultanpur, Sangareddy district.
Founded by Dhirajlal Kotadia in 2001,SMT became an early champion of the ‘Make in India’ initiative by being one of the first companies in Asia to indigenously develop & manufacture coronary stents.
Today, SMT is the largest developer, manufacturer and market leader of minimally invasive coronary stents (drug-eluting & bare metal), renal stents, PTCA balloon catheters and other cardio vascular accessories in India.
Beyond India, SMT also exports its portfolio of life saving devices to UK, Spain, Italy, Netherlands &over 60othercountries.
SMT operates a WHO-GMP certified manufacturing plant in Gujarat and two world-class R&D centers, including one in Ireland. The Company has a strong focus on R&D and has a number of pioneering achievements to its credit including being the first company in the world to receive the CE certification for a drug-eluting stent with biodegradable polymer.
Further, SMT has published several clinical studies in leading cardiac journals and has multiple process/product patents.The company keeps a highly customer-centric approach while distributing its innovative products & technologies through a well-entrenched direct sales network.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk